Generation of CD20-specific TCRs for TCR gene therapy of CD20(low) B-cell malignancies insusceptible to CD20-targeting antibodies

Immunotherapy of B-cell leukemia and lymphoma with CD20-targeting monoclonal antibodies (mAbs) has demonstrated clinical efficacy. However, the emergence of unresponsive disease due to low or absent cell surface CD20 urges the need to develop additional strategies. In contrast to mAbs, T-cells via t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Jahn, Lorenz, van der Steen, Dirk M., Hagedoorn, Renate S., Hombrink, Pleun, Kester, Michel G.D., Schoonakker, Marjolein P., de Ridder, Daniëlle, van Veelen, Peter A., Falkenburg, J.H. Frederik, Heemskerk, Mirjam H.M.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5363567/
https://ncbi.nlm.nih.gov/pubmed/27776339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12778
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars